Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast
Interventions: BIOLOGICAL: Imprime PGG|BIOLOGICAL: Pembrolizumab
Sponsor: HiberCell, Inc.
Collaborators: Merck Sharp & Dohme LLC